Jalia Karama Tucker, MD
Family Practice · Castroville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Clinica De Salud Del Valle De Salinas · County of Monterey · El Camino Health Medical Network LLC · Salud Para La Gente
Looking this up.
Hospitals listed: Community Hospital of the Monterey Peninsula · Salinas Valley Health Medical Center · Watsonville Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Tucker’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A169992 · Current
Licensed to practise in California · since 2020 · expires 2028-08-31 · Rosalind Franklin University, the Chicago Medical School.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Salinas Valley Health Medical CenterSalinas, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Salinas Valley Memorial Healthcare SystemPatients rate it 4 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.247, Oct 2024 – Sep 2025
- Watsonville Community HospitalWatsonville, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPatients rate it 3 of 5 · 66% would definitely recommend itOverall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Salinas Valley Health Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.247 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.32 (0.34 to 2.3) · 1,159 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.68 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.42 (143.23 to 253.6) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 112 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.2 · 203 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 536 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.1 · 239 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 2,377 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 7,593 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.43) · 7,999 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.97 (1.83 to 6.1) · 1,428 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.7 (0.16 to 3.24) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.31 (0.87 to 3.76) · 1,325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.78 (3.73 to 15.83) · 461 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.23 (1.52 to 8.95) · 453 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 279 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.48 (0 to 1.11) · 6,011 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.487 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.082 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.432 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.373 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 197 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 491 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 224 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8 · 660 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 569 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 485 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.9 (4.2 to 8.4) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 244 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 86 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 197 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 489 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,383 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Watsonville Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 4 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0 to 2.08) · 194 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.44 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 27 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.6 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.7 · 210 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.5 · 74 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 604 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 1,963 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,942 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.64 to 5.66) · 232 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.39) · 33 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.24 (0.54 to 3.95) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.86 (0 to 18.76) · 37 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.09 (0.81 to 9.36) · 32 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.21 to 3.24) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 1.35) · 1,464 cases | No different | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.351 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 82 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 52.2 · 119 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.4 · 221 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 182 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 28 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (9.5 to 17.2) · 311 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 46 cases | No different | Jan 2024 – Dec 2024 |
What patients said (264 patients answered, 12% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 77% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 66% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$3,867
Medicare paid this office $3,867 for 68 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (30+ min) | 18 | $1,792 | $100 |
| Hemoglobin a1c level | 18 | $190 | $10 |
| Blood glucose (sugar) level | 14 | $58 | $4 |
| Urinalysis, manual test | 14 | $55 | $3 |
Who their Medicare patients are
68 Original Medicare patients in 2024. Average age 69 · Women 68% · Also on Medicaid 52% · Health risk score 0.97. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 74% · Diabetes 46% · Depression 22% · Chronic kidney disease 19% · Coronary heart disease 18%.
The office billed $17,342, Medicare allowed $4,988 and paid $3,867; for 128 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$621,029 in 2024
Medicaid paid $621,029 for 8,298 billed services this clinician did in 2024, up to 407 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 4,213 | $604,781 |
| Short return visit (20+ min) | 2,928 | $6,740 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 40 | $3,629 |
| FETAL NON-STRESS TEST | 65 | $1,795 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 44 | $1,098 |
| Health behavior assessment | 49 | $972 |
| Health behavior intervention, individual, face-to-face; initial 30 minutes | 25 | $593 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 48 | $394 |
| Prenatal care, at-risk enhanced service; education | 12 | $379 |
| Patient education, not otherwise classified, non-physician provider, individual, per session | 16 | $341 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 83 | $110 |
| Screening test, pure tone, air only | 20 | $67 |
| 2024 | 8,298 | 25 | 407 | $621,029 |
| 2023 | 13,220 | 28 | 357 | $948,643 |
| 2022 | 8,515 | 24 | 195 | $581,329 |
| 2021 | 2,506 | 9 | 181 | $213,091 |
| 2020 | 94 | 2 | 24 | $14,255 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 6,073 | $877,719 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 380 | $33,904 |
| Short return visit (20+ min) | 3,176 | $18,312 |
| Health behavior intervention, individual, face-to-face; initial 30 minutes | 237 | $5,734 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 179 | $4,325 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 116 | $1,507 |
| Screening test, pure tone, air only | 113 | $1,311 |
| Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 55 | $1,262 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 72 | $897 |
| OFF/OP EST MAY X REQ PHY/QHP | 102 | $896 |
| FETAL NON-STRESS TEST | 51 | $665 |
| Health behavior assessment | 32 | $606 |
2022
| Clinic visit/encounter, all-inclusive | 3,609 | $524,106 |
| Short return visit (20+ min) | 1,943 | $19,169 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 177 | $16,012 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 104 | $5,609 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 104 | $3,573 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 121 | $2,599 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 206 | $2,496 |
| Screening test, pure tone, air only | 177 | $2,460 |
| Health behavior intervention, individual, face-to-face; initial 30 minutes | 106 | $2,246 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 58 | $864 |
| Medical nutrition therapy; re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 31 | $669 |
| Bilateral quantitative screening test of visual acuity | 134 | $556 |
2021
| Clinic visit/encounter, all-inclusive | 1,381 | $204,883 |
| Short return visit (20+ min) | 963 | $7,559 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 55 | $616 |
| HEMOGLOBIN | 25 | $25 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 25 | $9 |
| Return visit (30+ min) | 13 | $0 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 15 | $0 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 12 | $0 |
| Service | 17 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 72 | $14,030 |
| Short return visit (20+ min) | 22 | $225 |
Drugs they prescribed that Part D paid
$96,194
Pharmacies billed $96,194 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (23 of 871) in 2024. Above the middle of the specialty; the typical family practice clinician is at 2%.
750 generic and fewer than 11 brand-name prescriptions · $96,194 in drug cost · 27 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mounjaro | 17 | $16,461 | $968 |
| Jardiance | 11 | $10,909 | $992 |
| Gabapentin | 50 | $984 | $20 |
| Atorvastatin | 55 | $323 | $6 |
| Omeprazole | 14 | $255 | $18 |
See all 22 drugs
| Mounjaro | 17 | $16,461 | $968 |
| Jardiance | 11 | $10,909 | $992 |
| Gabapentin | 50 | $984 | $20 |
| Atorvastatin | 55 | $323 | $6 |
| Omeprazole | 14 | $255 | $18 |
| Levothyroxine | 20 | $240 | $12 |
| Hydrocodone-Acetaminophen | 17 | $221 | $13 |
| Mirtazapine | 13 | $183 | $14 |
| Metformin | 41 | $174 | $4 |
| Famotidine | 18 | $157 | $9 |
| Lisinopril | 33 | $157 | $5 |
| Alendronate | 26 | $135 | $5 |
| Bupropion Xl | 11 | $116 | $11 |
| Losartan | 30 | $110 | $4 |
| Lisinopril-Hydrochlorothiazide | 11 | $83 | $8 |
| Ibuprofen | 20 | $83 | $4 |
| Carvedilol | 11 | $77 | $7 |
| Fluticasone Propionate | 12 | $65 | $5 |
| Amlodipine Besylate | 31 | $63 | $2 |
| Clonazepam | 12 | $56 | $5 |
| Pregabalin | 12 | $54 | $4 |
| Hydrochlorothiazide | 18 | $36 | $2 |
Year by year
| 2024 | 871 | 161 | 3% (23) | None | $96,194 |
| 2023 | 738 | 98 | 2% (15) | 14% | $115,078 |
| 2022 | 568 | 103 | 3% (17) | None | $50,378 |
| 2021 | 137 | 52 | None | None | $11,141 |
| 2020 | 887 | 95 | 2% (13) | 14% | $55,025 |
| 2019 | 699 | 107 | 4% (29) | 18% | $45,042 |
| 2018 | 334 | 64 | 4% (14) | None | $23,541 |
| 2017 | 88 | 28 | None | None | $6,081 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Trulicity | 19 | $27,092 | $1,426 |
| Jardiance | 14 | $20,196 | $1,443 |
| Ozempic | 15 | $16,415 | $1,094 |
| Levemir Flexpen | 11 | $3,959 | $360 |
| Atorvastatin | 48 | $1,446 | $30 |
| Gabapentin | 35 | $961 | $27 |
| Amlodipine Besylate | 48 | $765 | $16 |
| Famotidine | 13 | $602 | $46 |
| Metformin | 31 | $593 | $19 |
| Omeprazole | 13 | $524 | $40 |
| Alendronate | 20 | $524 | $26 |
| Levothyroxine | 14 | $461 | $33 |
| Lisinopril | 26 | $428 | $16 |
| Losartan | 21 | $427 | $20 |
| Valsartan-Hydrochlorothiazide | 13 | $327 | $25 |
| Mirtazapine | 19 | $310 | $16 |
| Glimepiride | 12 | $221 | $18 |
| Bupropion | 11 | $155 | $14 |
| Meloxicam | 14 | $149 | $11 |
| Carvedilol | 11 | $139 | $13 |
| Clonazepam | 13 | $93 | $7 |
2022: 13 drugs
| Lantus Solostar | 11 | $3,955 | $360 |
| Diclofenac | 20 | $1,238 | $62 |
| Atorvastatin | 28 | $619 | $22 |
| Gabapentin | 31 | $517 | $17 |
| Metformin | 30 | $399 | $13 |
| Losartan | 12 | $322 | $27 |
| Levothyroxine | 13 | $319 | $25 |
| Lisinopril | 41 | $307 | $7 |
| Amlodipine Besylate | 22 | $234 | $11 |
| Hydrocodone-Acetaminophen | 14 | $185 | $13 |
| Metformin Hcl Er | 14 | $171 | $12 |
| Trazodone | 11 | $90 | $8 |
| Fluoxetine | 20 | $49 | $2 |
2021: 1 drug
| Amlodipine Besylate | 11 | $82 | $7 |
2020: 20 drugs
| Lantus | 16 | $6,634 | $415 |
| Budesonide Ec | 11 | $5,025 | $457 |
| Albuterol Sulfate Hfa | 21 | $1,114 | $53 |
| Levothyroxine | 32 | $770 | $24 |
| Atorvastatin | 40 | $690 | $17 |
| Omeprazole | 35 | $686 | $20 |
| Duloxetine | 15 | $631 | $42 |
| Gabapentin | 39 | $585 | $15 |
| Cyclobenzaprine | 19 | $429 | $23 |
| Amlodipine Besylate | 50 | $419 | $8 |
| Lisinopril | 40 | $342 | $9 |
| Metoprolol | 24 | $330 | $14 |
| Losartan | 39 | $286 | $7 |
| Hydrochlorothiazide | 46 | $209 | $5 |
| Metformin | 37 | $204 | $6 |
| Fluticasone Propionate | 11 | $166 | $15 |
| Carvedilol | 14 | $156 | $11 |
| Triamterene-Hydrochlorothiazid | 16 | $156 | $10 |
| Glipizide | 13 | $98 | $8 |
| Simvastatin | 11 | $37 | $3 |
2019: 19 drugs
| Incruse Ellipta | 15 | $7,135 | $476 |
| Atorvastatin | 50 | $1,227 | $25 |
| Levothyroxine | 31 | $566 | $18 |
| Gabapentin | 20 | $557 | $28 |
| Oxycodone-Acetaminophen | 15 | $510 | $34 |
| Omeprazole | 20 | $475 | $24 |
| Amlodipine Besylate | 36 | $356 | $10 |
| Metoprolol | 22 | $354 | $16 |
| Metformin Hcl Er | 12 | $292 | $24 |
| Spironolactone | 13 | $283 | $22 |
| Losartan | 30 | $267 | $9 |
| Lisinopril | 22 | $151 | $7 |
| Fluticasone Propionate | 11 | $128 | $12 |
| Mirtazapine | 14 | $123 | $9 |
| Metformin | 14 | $117 | $8 |
| Hydrochlorothiazide | 29 | $103 | $4 |
| Triamterene-Hydrochlorothiazid | 12 | $102 | $8 |
| Tramadol | 12 | $73 | $6 |
| Ibuprofen | 11 | $67 | $6 |
2018: 8 drugs
| Atorvastatin | 16 | $289 | $18 |
| Levothyroxine | 13 | $287 | $22 |
| Spironolactone | 12 | $271 | $23 |
| Losartan | 16 | $194 | $12 |
| Amlodipine Besylate | 15 | $187 | $12 |
| Lisinopril | 21 | $172 | $8 |
| Hydrochlorothiazide | 21 | $106 | $5 |
| Ibuprofen | 14 | $101 | $7 |
Money from drug and device companies
$30 in 2025
| 2025 | 1 | 1 | None | $30 |
| 2024 | 2 | 2 | None | $39 |
| 2023 | 2 | 2 | None | $45 |
| 2022 | 2 | 2 | None | $33 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Vraylar | $30 | 1 payment
|
See the published payment
| Abbvie | Meals · 2025-03-28 | Vraylar | $30 |
See earlier years (2024, 2023, 2022)
2024: $39
| Pfizer | Paxlovid | $22 | 1 payment
|
| Abbvie | Vraylar | $17 | 1 payment
|
2023: $45
| Pfizer | Prevnar 20 | $25 | 1 payment
|
| Lilly USA | Mounjaro | $20 | 1 payment
|
2022: $33
| Abbott Laboratories | Freestyle Libre 2 | $21 | 1 payment
|
| GlaxoSmithKline | Shingrix | $12 | 1 payment
|
Professional record
- NPI
- 1073040937
- Licence
- CA 169992California A169992: Current · expires 2028-08-31
- Group
- Clinica De Salud Del Valle De Salinas · County of Monterey · El Camino Health Medical Network LLC · Salud Para La Gente
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 440 Airport Blvd, Salinas, CA, 93905
- NPI first listed
- 2017-05-22
- NPI last updated
- 2020-11-09
- NPI record certified
- 2020-11-09
This is when the NPI record was last certified, not a medical board exam.